Clinical Trials Logo

Filter by:
NCT ID: NCT03403725 Terminated - Clinical trials for Metastatic Solid Tumors

MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study

CD205SHUTTLE
Start date: August 28, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with acceptable safety profile and that can be used in patients affected by CD205-positive solid tumors and Non-Hodgkin Lymphoma

NCT ID: NCT03400852 Terminated - Clinical trials for Muscular Dystrophy, Duchenne

A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy

BRAVE
Start date: July 27, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, double blind, placebo controlled, multiple dose study to examine the safety and efficacy of MNK-1411 in male subjects 4 to 8 years of age (inclusive) with Duchenne Muscular Dystrophy (DMD).

NCT ID: NCT03397394 Terminated - Bladder Cancer Clinical Trials

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

ATLAS
Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.

NCT ID: NCT03391765 Terminated - Clinical trials for Progressive Supranuclear Palsy (PSP)

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Start date: January 24, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).

NCT ID: NCT03388255 Terminated - Scleroderma Disease Clinical Trials

Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases

Start date: November 8, 2016
Phase: Phase 4
Study type: Interventional

This is a phase IV, single-arm, open-label clinical trial to evaluate the efficacy and safety of PLACENTEX ® Polydeoxyribonucleotide i.m. in patients with fibrotic and atrophic cutaneous lesions in scleroderma diseases during the inactive stage of the disease (experiencing dystrophic outcomes of the disease with no inflammatory component at the time of enrolment). The patients enrolled will be evaluated at study site at screening (V1), then after 3 months of treatment with PLACENTEX ® Polydeoxyribonucleotide (one vial per day for intra-muscular administration) (V2). After completion of the study treatment period, the patients will be followed for an additional period of 3 months without study medication, after which the patient will visit the site for the last visit (V3). 1 investigational site. 45 patients enrolled (included drop-outs).3 months of treatment with PLACENTEX ® Polydeoxyribonucleotide (one vial per day for intra-muscular administration).

NCT ID: NCT03387059 Terminated - Infertility Clinical Trials

Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle

ENDOMEDE
Start date: January 12, 2018
Phase: Phase 4
Study type: Interventional

This is a multicenter, prospective randomized controlled, interventional investigation to assess the safety and clinical performance of Forielle, a medical device for endometrial washing, in restoring favorable endometrial condition to implantation after Controlled Ovarian Stimulation (COS) during Assisted Reproductive Technique (ART).

NCT ID: NCT03387046 Terminated - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

INCREASE
Start date: March 26, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy.

NCT ID: NCT03381833 Terminated - Beta-Thalassemia Clinical Trials

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

This study is a Phase 2 multicenter, randomized, open-label, parallel-group study. The primary objective of the study is to evaluate the effect of LJPC-401 (synthetic human hepcidin) on iron levels in patients with transfusion-dependent beta thalassemia with myocardial iron overload.

NCT ID: NCT03381196 Terminated - Influenza A Clinical Trials

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Start date: January 21, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.

NCT ID: NCT03376321 Terminated - Influenza A Clinical Trials

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Start date: January 3, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.